# A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

> **NCT01602380** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 462 (actual)

## Conditions studied

- Hormone Receptor Positive Breast Cancer

## Interventions

- **DRUG:** faslodex 500mg
- **DRUG:** arimidex 1mg
- **DRUG:** faslodex dummy
- **DRUG:** arimidex dummy

## Key facts

- **NCT ID:** NCT01602380
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-17
- **Primary completion:** 2016-04-11
- **Final completion:** 2026-01-16
- **Target enrollment:** 462 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01602380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01602380, "A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01602380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*